Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells

Multiple myeloma (MM) is a malignancy of plasma cells that primarily reside in the bone marrow and in most cases involves the secretion of monoclonal paraproteins. Treatments for MM include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors, and immunomodulatory agents [1]. High-dose chemotherapy (HDC) in combination with autologous hematopoietic stem cell transplantation (auto-HSCT) has improved clinical responses [2-7] and the success of this treatment is partly due to the efficacy of pre-transplant HDC regimens.

Source: Experimental Hematology - January 14, 2020 Category: Hematology Authors: Benigno C. Valdez, Yang Li, David Murray, Yan Liu, Yago Nieto, Qaiser Bashir, Muzaffar H. Qazilbash, Borje S. Andersson Source Type: research